Impact of non-adherence to direct oral anticoagulants amongst Swedish patients with non-valvular atrial fibrillation: results from a real-world cost-utility analysis.
Carina Blomström LundqvistSara SjälanderLuis Alberto García-RodríguezÖrjan ÅkerborgGuanyi JinAmrit CaleyachettyMaria HuelsebeckKevin BowrinBernhard SchaeferHovsep MahdessianLucas HofmeisterLars-Åke LevinPublished in: Journal of medical economics (2022)
Adherence improving interventions for NVAF patients on DOACs such as chronic disease co-management and patient education can be cost-saving and cost-effective, within a range of costs that appear reasonable to the Swedish healthcare system.
Keyphrases
- direct oral anticoagulants
- atrial fibrillation
- venous thromboembolism
- end stage renal disease
- oral anticoagulants
- newly diagnosed
- chronic kidney disease
- catheter ablation
- left atrial
- ejection fraction
- healthcare
- heart failure
- left atrial appendage
- physical activity
- case report
- prognostic factors
- percutaneous coronary intervention
- adipose tissue
- quality improvement
- patient reported outcomes
- mitral valve
- patient reported